Orlance, Inc., a Seattle biotech developing next-generation DNA and RNA vaccines and therapeutics, has been awarded a three-year $3M National Institutes of Health (NIH) Phase II Small Business Innovation Research (SBIR) grant to advance its needle-free MACH-1 delivery platform and a universal influenza vaccine designed to protect from the annual flu and future pandemics toward Phase 1 clinical trials.
November 28, 2023
· 3 min read